Neurohormones in @entity1 with XXXX .

@entity1 @entity4688 @entity712 @entity1289 @entity2806 @entity2232 @entity19346 @entity2178 @entity951 @entity1063 @entity1002
Measurements of plasma neurohormones in @entity1 with @entity1002 are generally performed for research purpose rather than for diagnostic purpose or to guide therapy. These studies have shown that in @entity1 with @entity1002 , several neurohormonal systems were activated, even in the absence of symptoms of @entity712 . This suggested that the cardiovascular system was not in a steady state and pointed out potential culprits for the progression of the disease. It has also been shown that the levels of several of these markers, particularly plasma @entity1063 , had an important prognostic value. Another value of neurohormonal studies obviously is the design of new therapeutic approaches aimed at improving symptoms and prognosis. In this respect, important therapeutic successes have been obtained with agents that interfere with the actions of some of these neurohormonal systems, such as with the use of the @entity1289 ( @entity1289 ) inhibitors, particularly captopril and @entity4688 , and to a lesser extent, with beta-blockers. It can therefore be expected that, in the future, most @entity1 with severe @entity2806 will be treated with an @entity1289 inhibitor. Nonetheless, neurohormonal control is not complete with these drugs; powerful vasoconstrictor forces, such as @entity2232 , remain activated, and an escape of @entity2178 from the control of @entity1289 inhibition may exist. Thus, morbidity (e.g., progression towards @entity712 and @entity951 ) and mortality remain high despite treatment with @entity1289 inhibitors. In the search for future improvements, the new generation of long-acting @entity19346 is worth considering. Their afterload reducing action, coupled with powerful coronary vasodilation, might hypothetically delay the progression of @entity2806 .(ABSTRACT TRUNCATED AT 250 WORDS)
